Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are all type I human interferons equivalent?

G R Foster1, N B Finter

  • 1Imperial College School of Medicine, St Mary's Hospital, London, UK.

Journal of Viral Hepatitis
|July 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department - uncovering the iceberg?

Epidemiology and infection·2018
Same author

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.

Alimentary pharmacology & therapeutics·2017
Same author

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.

Journal of viral hepatitis·2017
Same author

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).

Journal of viral hepatitis·2017
Same author

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.

Alimentary pharmacology & therapeutics·2016
Same author

Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign.

HIV medicine·2016
Same journal

HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D.

Journal of viral hepatitis·2026
Same journal

Assessing the Utility of Shortened Read Time of the Abbott Bioline HCV Test to Predict Viremia.

Journal of viral hepatitis·2026
Same journal

Cardiac MRI Identifies Subclinical Myocardial Tissue Abnormalities in Individuals With Hepatitis C Regardless of Myocardial Damage Markers or Fibrosis Stage.

Journal of viral hepatitis·2026
Same journal

Drug Use and Social Connectivity Related to Hepatitis C Infection Among Rural People Who Use Drugs.

Journal of viral hepatitis·2026
Same journal

Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States.

Journal of viral hepatitis·2026
Same journal

Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review.

Journal of viral hepatitis·2026
See all related articles

Type I interferons, including interferon-alpha subtypes, exhibit distinct antiviral and immunostimulatory properties. Recent research reveals significant differences in how these subtypes interact with receptors and activate signaling pathways, impacting their immunomodulatory effects.

Area of Science:

  • Immunology
  • Virology
  • Cellular Signaling

Background:

  • Type I interferons are crucial cytokines with antiviral and immunostimulatory roles.
  • A long-standing debate exists regarding the functional similarities or differences among interferon-alpha subtypes.
  • Understanding these differences is key to their therapeutic applications.

Purpose of the Study:

  • To investigate the distinct interaction patterns of interferon-alpha subtypes with interferon receptor components.
  • To elucidate the differential activation of signaling pathways by various interferon-alpha subtypes.
  • To explore the immunomodulatory differences among Type I interferon subtypes.

Main Methods:

  • Analysis of interferon-alpha subtype interactions with interferon receptor components.

Related Experiment Videos

  • Investigation of downstream signaling pathway activation.
  • Assessment of immunomodulatory effects of different interferon-alpha subtypes.

    • Main Results:

    • Evidence suggests that different interferon-alpha subtypes interact uniquely with interferon receptor components.
    • Distinct signaling pathways are activated by various interferon-alpha subtypes.
    • Profound differences in the immunomodulatory properties of Type I interferon subtypes have been identified.

    Conclusions:

    • The findings highlight significant functional heterogeneity among interferon-alpha subtypes.
    • These subtype-specific differences may have important implications for immune responses.
    • Further research is needed to determine the clinical significance of these observed differences.